The report contains ten-year analysis with the following sections
contact us for pricing
Check out our sample pages |
Many companies now available
Search to find companies of interest
read summary of their published patent
the company report contains more information
aventis pharma | 2442 |
sanofi | 153 |
sanofi-aventis deutschland | 134 |
novexel | 67 |
centelion | 63 |
crouzet, joel | 28 |
rhone-poulenc rorer | 28 |
aventis holdings | 21 |
aventisub ii | 21 |
aventis pharma deutschland | 20 |
aventis pharma | 646 |
sanofi-aventis deutschland | 30 |
centelion | 26 |
novexel | 19 |
sanofi | 11 |
aventis holdings | 6 |
aventis pharma deutschland | 6 |
rhone-poulenc rorer | 6 |
mercken, luc | 5 |
hmr pharma | 4 |
sanofi | 47 |
aventis pharma | 23 |
aventisub | 1 |
pfizer ireland pharmaceuticals | 1 |
Title of patent family (most common patent title) |
Family members |
Filing year |
---|---|---|
antibodies that bind il-4 and/or il-13 and their uses | 171 | 2007 |
formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion | 71 | 2008 |
method for measuring resistance or sensitivity to docetaxel | 69 | 2004 |
cholesterol-producing yeast strains and uses thereof | 45 | 2004 |
novel antitumoral use of cabazitaxel | 43 | 2009 |
pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / … 🛈 | 42 | 1999 |
heterocyclic compounds which are active as inhibitors of beta lactamases | 42 | 2002 |
novel taxoid-based compositions | 39 | 2007 |
modified soluble fgf receptor fc fusions with improved biological activity | 38 | 2006 |
antitumour combinations containing a vegf inhibiting agent and irinotecan | 36 | 2007 |